A Randomized, Open-label,2-Period Crossover Study to Investigate the Bioequivalence of Ertugliflozin/Sitagliptin FDC (15 mg/50 mg) and co-administration of the individual components in healthy subjects

Trial Profile

A Randomized, Open-label,2-Period Crossover Study to Investigate the Bioequivalence of Ertugliflozin/Sitagliptin FDC (15 mg/50 mg) and co-administration of the individual components in healthy subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Ertugliflozin/sitagliptin (Primary) ; Ertugliflozin; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 05 Apr 2017 New trial record
    • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top